Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Raw Materials (2016 - 2024)

NovaBay Pharmaceuticals (NBY) has disclosed Raw Materials for 12 consecutive years, with $127000.0 as the latest value for Q4 2024.

  • On a quarterly basis, Raw Materials fell 86.53% to $127000.0 in Q4 2024 year-over-year; TTM through Dec 2024 was $127000.0, a 86.53% decrease, with the full-year FY2024 number at $127000.0, down 86.53% from a year prior.
  • Raw Materials was $127000.0 for Q4 2024 at NovaBay Pharmaceuticals, down from $160000.0 in the prior quarter.
  • In the past five years, Raw Materials ranged from a high of $1.3 million in Q2 2022 to a low of $127000.0 in Q4 2024.
  • A 5-year average of $671277.8 and a median of $618500.0 in 2021 define the central range for Raw Materials.
  • Peak YoY movement for Raw Materials: soared 641.51% in 2021, then plummeted 86.53% in 2024.
  • NovaBay Pharmaceuticals' Raw Materials stood at $159000.0 in 2020, then skyrocketed by 641.51% to $1.2 million in 2021, then increased by 7.97% to $1.3 million in 2022, then fell by 25.92% to $943000.0 in 2023, then tumbled by 86.53% to $127000.0 in 2024.
  • Per Business Quant, the three most recent readings for NBY's Raw Materials are $127000.0 (Q4 2024), $160000.0 (Q1 2024), and $943000.0 (Q4 2023).